SG11201900480YA - Anti-tim-3 antibodies - Google Patents
Anti-tim-3 antibodiesInfo
- Publication number
- SG11201900480YA SG11201900480YA SG11201900480YA SG11201900480YA SG11201900480YA SG 11201900480Y A SG11201900480Y A SG 11201900480YA SG 11201900480Y A SG11201900480Y A SG 11201900480YA SG 11201900480Y A SG11201900480Y A SG 11201900480YA SG 11201900480Y A SG11201900480Y A SG 11201900480YA
- Authority
- SG
- Singapore
- Prior art keywords
- indianapolis
- international
- indiana
- eli lilly
- company
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) Hu omits I iolo MEN! 010 110 1110 HOED (10) International Publication Number WO 2018/039020 Al WIPO I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/047261 (22) International Filing Date: 17 August 2017 (17.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,343 25 August 2016 (25.08.2016) US 62/469,753 10 March 2017 (10.03.2017) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: CARPENITO, Carmine; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). LI, Yiwen; c/o Eli Lilly and Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). SHEN, Yang; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHANG, Yi; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indi- ana 46206-6288 (US). (74) Agent: GARCIA, Carlos et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, O KM, ML, MR, NE, SN, TD, TG). O O Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 00 (54) Title: ANTI-TIM-3 ANTIBODIES 1-1 0 (57) : The present disclosure relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing \" protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and 0 ionizing radiation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662379343P | 2016-08-25 | 2016-08-25 | |
US201762469753P | 2017-03-10 | 2017-03-10 | |
PCT/US2017/047261 WO2018039020A1 (en) | 2016-08-25 | 2017-08-17 | Anti-tim-3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900480YA true SG11201900480YA (en) | 2019-02-27 |
Family
ID=59772703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900480YA SG11201900480YA (en) | 2016-08-25 | 2017-08-17 | Anti-tim-3 antibodies |
Country Status (26)
Country | Link |
---|---|
US (1) | US10253096B2 (en) |
EP (1) | EP3504240B1 (en) |
JP (1) | JP6502590B1 (en) |
KR (1) | KR102142903B1 (en) |
CN (1) | CN109563172B (en) |
AU (1) | AU2017316473B2 (en) |
BR (1) | BR112019001589A2 (en) |
CA (1) | CA3035042A1 (en) |
CL (1) | CL2019000488A1 (en) |
CO (1) | CO2019001646A2 (en) |
CR (1) | CR20190079A (en) |
DO (1) | DOP2019000027A (en) |
EC (1) | ECSP19013181A (en) |
ES (1) | ES2908916T3 (en) |
IL (1) | IL264159A (en) |
JO (1) | JOP20190013A1 (en) |
MA (1) | MA46041A (en) |
MX (1) | MX2019002064A (en) |
PE (1) | PE20190630A1 (en) |
PH (1) | PH12019500369A1 (en) |
SG (1) | SG11201900480YA (en) |
TN (1) | TN2019000040A1 (en) |
TW (2) | TWI639616B (en) |
UA (1) | UA122929C2 (en) |
WO (1) | WO2018039020A1 (en) |
ZA (1) | ZA201900373B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3274370T (en) | 2015-03-23 | 2020-02-10 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
TWI752950B (en) | 2016-04-12 | 2022-01-21 | 丹麥商賽門弗鎭公司 | Anti-tim-3 antibodies and compositions |
PE20190418A1 (en) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES |
CN110023338A (en) * | 2016-12-08 | 2019-07-16 | 伊莱利利公司 | For the anti-TIM-3 antibody with anti-PD-L1 antibody combination |
JOP20190133A1 (en) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies |
CN110621698B (en) | 2017-04-05 | 2024-04-12 | 法国施维雅药厂 | Combination therapies targeting PD-1, TIM-3 and LAG-3 |
JOP20190222A1 (en) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | Anti-pd-l1-anti-tim-3 bispecific antibodies |
BR112020018539A2 (en) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | ANTIBODIES AGAINST MICA AND / OR MICB AND USES OF THE SAME |
WO2019196911A1 (en) | 2018-04-12 | 2019-10-17 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding tim-3 and use thereor |
CN112543647B (en) * | 2018-08-28 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | TIM3 antibody pharmaceutical composition and application thereof |
WO2020093023A1 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Anti-tim-3 antibodies |
WO2020093024A2 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Methods of administering anti-tim-3 antibodies |
US20220089721A1 (en) | 2018-12-19 | 2022-03-24 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
EP3908610A1 (en) | 2019-01-11 | 2021-11-17 | Eli Lilly and Company | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer |
EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
JP2022534982A (en) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | Cellular localization signatures and their uses |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
CN113164601B (en) * | 2019-09-19 | 2023-09-29 | 上药生物治疗(香港)有限公司 | Isolated antigen binding proteins and uses thereof |
WO2021141977A1 (en) | 2020-01-07 | 2021-07-15 | Board Of Regents, The University Of Texas System | Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy |
BR112023003553A2 (en) | 2020-08-31 | 2023-04-04 | Bristol Myers Squibb Co | CELLULAR LOCATION AND IMMUNOTHERAPY SIGNATURE |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
MX2023007734A (en) | 2020-12-28 | 2023-08-21 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof. |
MX2023007650A (en) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Subcutaneous administration of pd1/pd-l1 antibodies. |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
IL310773A (en) | 2021-09-02 | 2024-04-01 | Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
EP1467759A4 (en) | 2002-01-30 | 2006-05-31 | Brigham & Womens Hospital | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
EP2417984B1 (en) * | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
HUE040213T2 (en) * | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-tim-3 antibody |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CA2958643A1 (en) | 2014-07-07 | 2016-01-14 | Dana Farber Cancer Institute, Inc. | Methods of treating cancer |
AU2015340056A1 (en) * | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
CN107001475B (en) * | 2014-11-06 | 2021-01-29 | 豪夫迈·罗氏有限公司 | anti-TIM 3 antibodies and methods of use |
EP3218409A2 (en) * | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
CN104592388B (en) * | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | A kind of antigen-binding portion thereof of the monoclonal antibody of anti-human Tim 3 |
MA41867A (en) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3) |
CN110023338A (en) * | 2016-12-08 | 2019-07-16 | 伊莱利利公司 | For the anti-TIM-3 antibody with anti-PD-L1 antibody combination |
JOP20190133A1 (en) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies |
JOP20190222A1 (en) * | 2017-04-11 | 2019-09-24 | Zymeworks Inc | Anti-pd-l1-anti-tim-3 bispecific antibodies |
-
2017
- 2017-06-16 JO JOP/2019/0013A patent/JOP20190013A1/en unknown
- 2017-08-14 TW TW106127417A patent/TWI639616B/en not_active IP Right Cessation
- 2017-08-14 TW TW107134877A patent/TW201900684A/en unknown
- 2017-08-17 SG SG11201900480YA patent/SG11201900480YA/en unknown
- 2017-08-17 CR CR20190079A patent/CR20190079A/en unknown
- 2017-08-17 MA MA046041A patent/MA46041A/en unknown
- 2017-08-17 CA CA3035042A patent/CA3035042A1/en not_active Abandoned
- 2017-08-17 KR KR1020197005011A patent/KR102142903B1/en active IP Right Grant
- 2017-08-17 MX MX2019002064A patent/MX2019002064A/en unknown
- 2017-08-17 AU AU2017316473A patent/AU2017316473B2/en not_active Ceased
- 2017-08-17 PE PE2019000397A patent/PE20190630A1/en unknown
- 2017-08-17 BR BR112019001589A patent/BR112019001589A2/en not_active IP Right Cessation
- 2017-08-17 TN TNP/2019/000040A patent/TN2019000040A1/en unknown
- 2017-08-17 UA UAA201901191A patent/UA122929C2/en unknown
- 2017-08-17 ES ES17761633T patent/ES2908916T3/en active Active
- 2017-08-17 EP EP17761633.1A patent/EP3504240B1/en active Active
- 2017-08-17 WO PCT/US2017/047261 patent/WO2018039020A1/en unknown
- 2017-08-17 CN CN201780052147.7A patent/CN109563172B/en active Active
- 2017-08-17 JP JP2018552182A patent/JP6502590B1/en active Active
- 2017-08-17 US US15/679,190 patent/US10253096B2/en active Active
-
2019
- 2019-01-09 IL IL264159A patent/IL264159A/en unknown
- 2019-01-18 ZA ZA2019/00373A patent/ZA201900373B/en unknown
- 2019-02-07 DO DO2019000027A patent/DOP2019000027A/en unknown
- 2019-02-21 PH PH12019500369A patent/PH12019500369A1/en unknown
- 2019-02-22 CL CL2019000488A patent/CL2019000488A1/en unknown
- 2019-02-22 CO CONC2019/0001646A patent/CO2019001646A2/en unknown
- 2019-02-22 EC ECSENADI201913181A patent/ECSP19013181A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |